U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H15N7O2S3
Molecular Weight 337.449
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FAMOTIDINE

SMILES

C(CSCc1csc(n1)NC(=N)N)C(=N)NS(=O)(=O)N

InChI

InChIKey=XUFQPHANEAPEMJ-UHFFFAOYSA-N
InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/famotidine.html

Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.

CNS Activity

Curator's Comment:: Famotidine is a potent highly selective H2 receptor antagonist which crosses the blood-brain barrier.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.3 µM [IC50]
6.7 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
PEPCID

Approved Use

PEPCID is indicated in: 1. Short-term treatment of active duodenal ulcer. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Short-term treatment of active benign gastric ulcer. 4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm treatment of patients with symptoms of GERD PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)

Launch Date

5.29632002E11
Curative
PEPCID

Approved Use

PEPCID is indicated in: 1. Short-term treatment of active duodenal ulcer. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Short-term treatment of active benign gastric ulcer. 4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm treatment of patients with symptoms of GERD PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)

Launch Date

5.29632002E11
Primary
PEPCID

Approved Use

PEPCID is indicated in: 1. Short-term treatment of active duodenal ulcer. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Short-term treatment of active benign gastric ulcer. 4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm treatment of patients with symptoms of GERD PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)

Launch Date

5.29632002E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
73 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
424 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
82.5%
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 mg/kg 2 times / day steady, oral
Recommended
Dose: 0.5 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 0.5 mg/kg, 2 times / day
Sources:
unhealthy, 11 - 15 years
n = 8
Health Status: unhealthy
Condition: gastric or duodenal ulcers
Age Group: 11 - 15 years
Sex: M
Population Size: 8
Sources:
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 20 - 70 years
n = 10
Health Status: unhealthy
Condition: COVID-19
Age Group: 20 - 70 years
Sex: M+F
Population Size: 10
Sources:
Other AEs: Dizziness, Dry skin...
Other AEs:
Dizziness (grade 1, 2 patients)
Dry skin (grade 1, 1 patient)
Insomnia (grade 1, 1 patient)
Gastrointestinal disorder (NOS) (grade 1, 1 patient)
Forgetfulness (grade 1, 1 patient)
Sources:
1 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 1 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 1 mg/kg, 1 times / day
Sources:
unhealthy, 6 - 15 years
n = 6
Health Status: unhealthy
Condition: gastric or duodenal ulcers
Age Group: 6 - 15 years
Sex: M
Population Size: 6
Sources:
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
Other AEs: Anemia, Nausea...
Other AEs:
Anemia (2 patients)
Nausea (6 patients)
Dyspepsia (5 patients)
Diarrhea (5 patients)
Constipation (4 patients)
Abdominal pain upper (3 patients)
Gastroesophageal reflux disease (2 patients)
Vomiting (2 patients)
Stomach discomfort (2 patients)
Abdominal pain (2 patients)
Edema peripheral (2 patients)
Arthralgia (1 patient)
Back pain (2 patients)
Headache (3 patients)
Hypertension (3 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dry skin grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 20 - 70 years
n = 10
Health Status: unhealthy
Condition: COVID-19
Age Group: 20 - 70 years
Sex: M+F
Population Size: 10
Sources:
Forgetfulness grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 20 - 70 years
n = 10
Health Status: unhealthy
Condition: COVID-19
Age Group: 20 - 70 years
Sex: M+F
Population Size: 10
Sources:
Gastrointestinal disorder (NOS) grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 20 - 70 years
n = 10
Health Status: unhealthy
Condition: COVID-19
Age Group: 20 - 70 years
Sex: M+F
Population Size: 10
Sources:
Insomnia grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 20 - 70 years
n = 10
Health Status: unhealthy
Condition: COVID-19
Age Group: 20 - 70 years
Sex: M+F
Population Size: 10
Sources:
Dizziness grade 1, 2 patients
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 20 - 70 years
n = 10
Health Status: unhealthy
Condition: COVID-19
Age Group: 20 - 70 years
Sex: M+F
Population Size: 10
Sources:
Arthralgia 1 patient
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
Abdominal pain 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
Anemia 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
Back pain 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
Edema peripheral 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
Gastroesophageal reflux disease 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
Stomach discomfort 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
Vomiting 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
Abdominal pain upper 3 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
Headache 3 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
Hypertension 3 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
Constipation 4 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
Diarrhea 5 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
Dyspepsia 5 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
Nausea 6 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Co-administed with::
ibuprofen(800 mg)
Sources:
unhealthy, adult
n = 1022
Health Status: unhealthy
Condition: chronic pain and inflammation of stomach
Age Group: adult
Sex: M+F
Population Size: 1022
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
weak
likely (co-administration study)
Comment: may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate; can't find inhibition value
Page: 6.0
yes [IC50 114 uM]
yes [IC50 28 uM]
yes [IC50 6.7 uM]
yes [Inhibition 100 uM]
yes [Inhibition 100 uM]
yes [Inhibition 100 uM]
yes [Ki 0.6 uM]
yes [Ki 9.7 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure.
1992 Mar
[Tolerance of famotidine. Study of network of sentinel physicians in pharmaco-vigilance].
1992 May-Jun
Prostacyclin analog prevents stress-induced expression of immediate early genes and gastric mucosal lesions in the rat stomach.
1999
Amantadine-induced cortical myoclonus.
2001 Jan 23
Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment.
2001 May
Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.
2002
Effects of omeprazole and famotidine on fibroblast growth factor-2 during artificial gastric ulcer healing in humans.
2002 Apr
Radioprotective properties of histamine H2 receptor antagonists: present and future prospects.
2003 Jun
Effect of exogenous administration of transforming growth factor-beta and famotidine on the healing of duodenal ulcer under the impact of indomethacin.
2003 Jun
On the mechanisms underlying histamine induction of gastric mucosal lesions in rats with partial gastric vascular occlusion.
2003 Jun
Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A).
2004 Oct 25
Effects of cimetidine-like drugs on recombinant GABAA receptors.
2004 Oct 8
Carrier-mediated uptake of H2-receptor antagonists by the rat choroid plexus: involvement of rat organic anion transporter 3.
2004 Sep
Switching of H(2)-Receptor Antagonists to Over-the-Counter Status in Finland : Implications for Consumption and Adverse Effects.
2005
[Gastroprotective effects of histamine H2-receptor blockers in Helicobacter-like gastric mucosa lesions].
2005
Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes.
2005 Apr
Effect of pre-operative short course famotidine on tumor infiltrating lymphocytes in colorectal cancer: a double blind, placebo controlled, prospective randomized study.
2005 Dec
Synergistic action of famotidine and chlorpheniramine on acetic acid-induced chronic gastric ulcer in rats.
2005 Dec 7
Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis.
2005 Feb
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Comparison of hemostatic effects by route of H2 receptor antagonist administration following endoscopic mucosal resection in patients with neoplastic gastric lesions.
2005 Jun
Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.
2005 Jun
New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline.
2005 Jun
Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies.
2005 Jun
Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia.
2005 Jun
[Complex evaluation of the action of inhibitors of hydrochloric acid secretion on gastric function in ulcer disease].
2006
Histamine mediates the stimulatory action of ghrelin on acid secretion in rat stomach.
2006 Aug
Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes.
2006 Aug
Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy).
2006 Dec
In vitro availability of metformin in presence of h(2) receptor antagonists.
2006 Jan
Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine.
2006 May
Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2.
2006 Oct
Expression of HSP72 in the gastric mucosa is regulated by gastric acid in rats-correlation of HSP72 expression with mucosal protection.
2006 Oct 20
Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies.
2006 Oct 3
Histamine stimulation of MMP-1(collagenase-1) secretion and gene expression in gastric epithelial cells: role of EGFR transactivation and the MAP kinase pathway.
2007
The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial.
2007 Jan
[Clinical study on effect of Jianwei Yuyang Granule in treating patients with gastric ulcer].
2007 Jul
Novel role of famotidine in downregulation of matrix metalloproteinase-9 during protection of ethanol-induced acute gastric ulcer.
2007 Jul 15
Gastric antisecretory drugs induce leukocyte-endothelial cell interactions through gastrin release and activation of CCK-2 receptors.
2007 Oct
Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
2008 Feb
Antinociception induced by central administration of histamine in the formalin test in rats.
2008 Jul-Sep
Risk factors for the development of gastric mucosal lesions in rheumatoid arthritis patients receiving long-term nonsteroidal anti-inflammatory drug therapy and the efficacy of famotidine obtained from the FORCE study.
2009
Phosphodiesterase isozymes involved in regulating acid secretion in the isolated mouse stomach.
2009 Dec
[Neurological complications of acute intermittent porphyria precipitated by porphyrinogenic drugs and efficiency of heme-arginate treatment].
2009 Sep
Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
2010 Apr
Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study.
2010 Apr
Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.
2010 Jul 30
Hepatoprotective, antinociceptive and antioxidant activities of cimetidine, ranitidine and famotidine as histamine H2 receptor antagonists.
2011 Feb
Patents

Sample Use Guides

The recommended adult oral dosage for active duodenal ulcer is 40 mg once a day at bedtime. Most patients heal within 4 weeks.
Route of Administration: Oral
Famotidine (10-1,000 µM) inhibited methadone and oxycodone cytochrome P450-dependent metabolism >50%.
Name Type Language
FAMOTIDINE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
FLUXID
Brand Name English
FAMOTIDINE COMPONENT OF PEPCID COMPLETE
Common Name English
GASTER
Brand Name English
MUCLOX
Brand Name English
AMFAMOX
Brand Name English
FAMOXAL
Brand Name English
PEPDUL
Brand Name English
(1-AMINO-3-(((2-((DIAMINOMETHYLENE)AMINO)-4-THIAZOLYL)METHYL)THIO)PROPYLIDENE)SULFAMIDE
Systematic Name English
FAMOTIDINE [MART.]
Common Name English
PEPCIDINE
Brand Name English
LECEDIL
Brand Name English
MOTIAX
Brand Name English
L 643341
Code English
GANOR
Brand Name English
FAMOTIDINE [WHO-DD]
Common Name English
FAMOTIDINE [MI]
Common Name English
FAMOTIDINE [INN]
Common Name English
PEPCID COMPLETE COMPONENT FAMOTIDINE
Common Name English
GASTRIDIN
Brand Name English
FAMODIL
Brand Name English
FAMOTIDINE [VANDF]
Common Name English
FAMOTIDINE [USP MONOGRAPH]
Common Name English
YM-11170
Code English
GASTROPEN
Brand Name English
PROPANIMIDAMIDE, N'-(AMINOSULFONYL)-3-(((2-((DIAMINOMETHYLENE)AMINO)-4-THIAZOLYL)METHYL)THIO)-
Systematic Name English
FAMOTIDINE [HSDB]
Common Name English
PEPCIDAC
Brand Name English
PEPDINE
Brand Name English
FADUL
Brand Name English
FAMOTIDINE [USP-RS]
Common Name English
FAMOTIDINE [USAN]
Common Name English
FAMOTIDINE [ORANGE BOOK]
Common Name English
FAMOSAN
Brand Name English
PEPCID
Brand Name English
FAMOTIDINE [EP MONOGRAPH]
Common Name English
NSC-757810
Code English
FAMOTIDINE [USP]
Common Name English
MK-208
Code English
3-((((2-(DIAMINOMETHYLENE)AMINO)-4-THIAZOLYL)METHYL)THIO)-N-SULFAMOYLPROPIONAMIDINE
Common Name English
Classification Tree Code System Code
WHO-ATC A02BA03
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
NDF-RT N0000175784
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
WHO-VATC QA02BA03
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
NCI_THESAURUS C29702
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
WHO-ATC A02BA53
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
LIVERTOX 399
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
WHO-VATC QA02BA53
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
NDF-RT N0000000151
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
Code System Code Type Description
LACTMED
Famotidine
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY
EPA CompTox
76824-35-6
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY
DRUG BANK
DB00927
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY
USP_CATALOG
1269200
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY USP-RS
MESH
D015738
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY
EVMPD
SUB07503MIG
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY
INN
5217
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY
IUPHAR
7074
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY
PUBCHEM
3325
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY
MERCK INDEX
M5241
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL902
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY
RXCUI
4278
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
FAMOTIDINE
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY
DRUG CENTRAL
1129
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY
HSDB
3572
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY
NCI_THESAURUS
C29045
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY
FDA UNII
5QZO15J2Z8
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY
CAS
76824-35-6
Created by admin on Fri Jun 25 21:04:38 UTC 2021 , Edited by admin on Fri Jun 25 21:04:38 UTC 2021
PRIMARY